Paul A. Khavari, MD, PhD
Academic Appointments
- Professor, Dermatology
- Member, Child Health Research Institute
- Member, Stanford Cancer Institute
- Member, Bio-X
Key Documents
Contact Information
-
Clinical Offices
450 Broadway Street Pavilion B Redwood City, CA 94063 Tel Work (650) 497-8000 Fax (650) 497-8001
- Academic Offices
Personal Information EmailAlternate Contact Luana Morcom Program Director Email Tel Work 650/498-6295Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cutaneous (Dermatologic) Oncology
- Dermatology
- General Dermatology
Administrative Appointments
- Co-Director, Stanford Program in Epithelial Biology (1999 - present)
- Chair Department of Dermatology, Stanford University School of Medicine (2010 - present)
Professional Education
| Residency: | Stanford University School of Medicine CA (1991) |
| Board Certification: | Dermatology, American Board of Dermatology (1992) |
| Residency: | Yale - New Haven Hospital CT (1990) |
| Internship: | *Yale-New Haven Hospital CT (1989) |
| Medical Education: | Yale University School of Medicine-Graduate CT (1988) |
Postdoctoral Advisees
Xiaomin Bao, Ross Flockhart, Carolyn Lee, Bryan Sun, Alexander Ungewickell, Ashley Zehnder
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
Our experimental focus is on the mammalian setting, including mouse genetics, human genetics and new human tissue platforms. The latter encompass human skin regenerated on immune deficient mice as well as organotypic constructs with epithelial and stromal cells embedded within architecturally faithful mesenchyma in vitro. These new models, which we term Multi-Functional Human Tissue Genetics, allow up to 10 alleles or more to be altered simultaneously, permitting genetic experiments with an unprecedented degree of rapidity and complexity.
Stem cell biology and differentiation
In stratified epithelia proliferative basal cells adherent to the underlying basement membrane undergo cell cycle arrest then outward migration and terminal differentiation. This process is mediated by 2 mutually exclusive programs of gene expression: 1) an undifferentiated program supporting proliferation by stem cells within the basal layer and 2) a differentiation program instructing growth arrest and differentiation-associated programmed cell death in suprabasal layers. The control of this transition from epithelial stem cell to differentiated corneocyte, which is abnormal in epidermal cancers, is not well understood. We are currently pursuing studies of the dominant signaling and gene regulatory networks that control this process, including the Ras/MAPK cascade, which is required for stem cell-mediated self-renewal and the p53 transcription factor family member, p63, which is required for epidermal differentiation.
Epigenetic regulation by histone modifying proteins and noncoding RNA
In addition to classical gene regulatory networks noted above, we have recently identified a central role for additional biologic mechanisms, namely gene regulation by chromatin regulators and by noncoding RNAs. Epigenetic control of gene expression lasts through multiple cell divisions without alterations in primary DNA sequence and can occur via mechanisms that include histone modification and DNA methylation. Noncoding RNA sequences can regulate gene expression via interactions with epigenetic and other control mechanisms. The function of histone modifying epigenetic regulators and noncoding RNA as central mediators of epithelial stem cell renewal and differentiation represent major emerging areas of study in the lab.
Cancer
Skin malignancies, including epidermal squamous cell carcinoma (SCC), alone account for nearly as many cancers as all other tissues combined. Progress in understanding epithelial carcinogenesis has been hindered in the past by a lack of models that faithfully recapitulate the 3-dimensional architecture of tumor-stroma co-evolution. To address this and to also study the oncogenic potential of unregulated function of dominant regulators of epithelial homeostasis noted above, we developed Multi-Functional Human Tissue Genetics noted above which, when combined with skin tissue regeneration on immune deficient mice, has permitted the molecular reconstruction of events sufficient to trigger human cancer. These models are being used to systematically elucidate proteins required for cutaneous carcinogenesis and to test their potential role as therapeutic targets.
Molecular Therapeutics
Epithelial tissues in general and skin in particular offer an attractive site for development of new approaches in molecular therapeutics. A family of human genetic skin diseases is characterized by defective epithelial gene expression. Among the most severe of these are subtypes of epidermolysis bullosa (EB) and lamellar ichthyosis (LI). We have developed approaches for high efficiency gene transfer to EB and LI patient skin tissue that are corrective at biochemical, histologic, clinical and functional levels. In addition to EB subtypes and LI, similar corrective efforts have also been undertaken with a number of other genetic skin disorders.
Clinical Trials
- Recruiting Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
- Recruiting Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
- Recruiting Characteristics of Patients With Dystrophic Epidermolysis Bullosa
- Recruiting Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
- Recruiting Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Publications
- ACTL6a enforces the epidermal progenitor state by suppressing SWI/SNF-dependent induction of KLF4. Cell Stem Cell. 2013; (2): 193-203
- Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature. 2013; (7431): 231-5
- IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med. 2013; (5): 626-30
- ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. Dev Cell. 2012; (3): 669-77
- DNMT1 maintains progenitor function in self-renewing somatic tissue. Nature. 2010; (7280): 563-7
- Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia Nature Medicine. 2010: 1450-1455

